Patents by Inventor Houman Ashrafian
Houman Ashrafian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210236512Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic immunoglobulin driven B cell disease with a T cell component. The invention also provides pharmaceutical compositions containing such compounds.Type: ApplicationFiled: January 31, 2019Publication date: August 5, 2021Applicant: ZARODEX THERAPEUTICS LIMITEDInventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE
-
Publication number: 20210236513Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic immunoglobulin driven B cell disease. The invention also provides pharmaceutical compositions containing such compounds.Type: ApplicationFiled: January 31, 2019Publication date: August 5, 2021Applicant: ZARODEX THERAPEUTICS LIMITEDInventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE
-
Publication number: 20210137941Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic IgE driven B cell disease. The invention also provides pharmaceutical compositions containing such compounds.Type: ApplicationFiled: January 31, 2019Publication date: May 13, 2021Applicant: ZARODEX THERAPEUTICS LIMITEDInventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE
-
Patent number: 9468634Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof.Type: GrantFiled: March 15, 2013Date of Patent: October 18, 2016Assignee: Heart Metabolics LimitedInventors: Houman Ashrafian, Michael Paul Frenneaux
-
Patent number: 9457017Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment program for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof.Type: GrantFiled: March 15, 2013Date of Patent: October 4, 2016Assignee: Heart Metabolics LimitedInventors: Houman Ashrafian, Michael Paul Frenneaux
-
Publication number: 20140194466Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt or enantiomer thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt or enantiomer thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof.Type: ApplicationFiled: February 21, 2014Publication date: July 10, 2014Applicant: The University of BirminghamInventors: Houman ASHRAFIAN, Michael Paul FRENNEAUX
-
Patent number: 8697728Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof.Type: GrantFiled: May 11, 2010Date of Patent: April 15, 2014Assignee: The University of BirminghamInventors: Houman Ashrafian, Michael Paul Frenneaux
-
Patent number: 8440697Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of HfnEF, as well as to a method of treating HfnEF, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HFnEF. The invention further relates to a treatment program for treating HFnEF, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HFnEF or the symptoms thereof.Type: GrantFiled: May 21, 2010Date of Patent: May 14, 2013Assignee: Heart Metabolics LimitedInventors: Houman Ashrafian, Michael P. Frenneaux
-
Publication number: 20120122925Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof.Type: ApplicationFiled: May 11, 2010Publication date: May 17, 2012Applicant: HEART METABOLICS LIMITEDInventors: Houman Ashrafian, Michael Paul Frenneaux
-
Publication number: 20100331364Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of HfnEF, as well as to a method of treating HfnEF, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HFnEF. The invention further relates to a treatment programme for treating HFnEF, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HFnEF or the symptoms thereof.Type: ApplicationFiled: May 21, 2010Publication date: December 30, 2010Applicant: HEART METABOLICS LIMITEDInventors: Houman Ashrafian, Michael P. Frenneaux
-
Publication number: 20100008908Abstract: The treatment of heart failure by administering a therapeutically effective amount of an agent that inhibits hypoxia-inducible factor (HIF). Such agents include small molecule chemical agents and biological agents.Type: ApplicationFiled: April 2, 2009Publication date: January 14, 2010Applicant: Isis Innovation LimitedInventors: Houman Ashrafian, Hugh Watkins